Explore Brainsway Ltd. Q4 2025 earnings highlights, financial performance, strategic initiatives, and future outlook in mental health treatment.

In the fourth quarter and full year 2025, Brainsway Ltd. American Depositary Shares demonstrated remarkable financial performance, achieving a 27% increase in revenue compared to the previous year. As the company continues to expand its footprint in the mental health treatment sector, several strategic initiatives and a robust future outlook have positioned it for sustained growth. This article delves into the key highlights from the earnings call, providing insights into Brainsway's financial performance, strategic initiatives, and future outlook.

Financial Performance

Brainsway reported impressive financial metrics for the fourth quarter, with revenue soaring to $14.5 million, marking a 27% increase from $11.4 million in Q4 2024. For the full year, the company achieved revenue of $52.2 million, also a 27% increase compared to $41 million in 2024. These figures not only surpassed the company's guidance but also reflected a steady trend of profitability, marking 10 consecutive quarters of profitability.

Key Metrics

• Gross Profit for Q4: $11.1 million, up from $8.5 million in the prior year.
• Gross Margin: Increased to 76% for Q4 compared to 75% year-over-year.
• Net Income for Q4: $2.9 million, compared to $1.5 million in Q4 2024.
• Adjusted EBITDA: Increased to $2.3 million from $1.5 million in the prior year period.
• Operating Income: Approximately $1.9 million, up from $0.4 million in Q4 2024.

The company's strong performance is attributed to its expanding backlog, which reached $70 million, a 43% increase year-over-year. This growth is indicative of robust demand for its DeepTMS systems and a strategic shift towards long-term leasing agreements, providing stability and visibility into future revenues.

Strategic Initiatives

Brainsway's strategic initiatives focus on enhancing its product offerings and expanding market reach. The company has made significant advancements in its DeepTMS technology, which targets mental health disorders such as depression and anxiety.

Growth through Leasing Model

A pivotal decision made by the company two years ago to target large enterprise customers has paid off, with many now engaged in long-term leasing agreements. This transition has allowed Brainsway to build a recurring revenue model, which provides greater stability and growth potential. As a result, the company has seen a high rate of customer renewals.

FDA Approvals and Clinical Research

In Q4 2025, Brainsway received FDA clearance for the DeepTMS system to be used as an adjunct therapy for adolescents aged 15 to 21 suffering from major depressive disorder. This expansion significantly broadens the addressable patient population, with an estimated 5 million adolescents in the U.S. having experienced a major depressive episode in the past year.

Additionally, the company announced a $2.5 million NIH grant awarded for a study on DeepTMS for alcohol use disorder. This research aims to address a significant public health issue, as approximately 29 million Americans are affected by alcohol use disorder, with high relapse rates.

Innovative Treatment Protocols

The introduction of the SWIFT DeepTMS protocol aims to enhance treatment efficiency and patient access. This protocol reduces the number of required office visits by 70%, which is expected to improve patient retention and clinical outcomes. Furthermore, collaborations with payers such as Premera Blue Cross and Highmark Blue Cross Blue Shield are vital for expanding coverage and clinical adoption of the new protocol.

Future Outlook

Looking ahead, Brainsway's management has expressed optimistic guidance for 2026, projecting revenue between $66 million to $68 million, representing year-over-year growth of 27% to 30%. The anticipated operating income is expected to range between 13% to 14% of revenue, with adjusted EBITDA projected at $12 million to $14 million, indicating a growth of 86% to 100% over 2025.

Market Positioning

As the company continues to innovate, it aims to leverage its strong market position to develop a portfolio of data-driven, technology-enabled neuromodulation solutions. This strategy includes an initial investment in Neuralief, which has developed the Prolif RX, the first wearable non-invasive multichannel brain neuromodulation platform designed for at-home use. This move aligns with Brainsway's long-term vision to integrate multiple treatment modalities across various care settings.

Conclusion

In summary, Brainsway Ltd. American Depositary Shares has demonstrated impressive financial performance in Q4 2025, driven by strategic initiatives that focus on innovation and expanding market reach. With a robust recurring revenue model and strategic partnerships, the company is well-positioned for future growth. The guidance for 2026 indicates sustained momentum, making Brainsway an attractive investment opportunity for those interested in the evolving mental health treatment landscape. Investors should closely monitor the company’s progress as it continues to innovate and expand its offerings in the mental health sector.